SIGNAL PROCESSING CIRCUIT, SEMICONDUCTOR PIXEL DETECTOR, INFORMATION PROCESSING METHOD, PROGRAM, INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, AND DEVICE
[Problem] To provide a signal processing circuit capable of specifying a change in signal strength due to a difference in the reaction position of radiation in the depth direction of a semiconductor with higher accuracy than in the prior art, and thereby more appropriately correcting a tail on a low energy side. Also, to provide a semiconductor pixel detector, an information processing method, a program, an information processing device, an information processing system, a device, and the like. [Solution] An embodiment of the present invention provides signal processing circuits that are respectively mounted on semiconductor pixels in a semiconductor pixel detector and that each process a signal generated in the semiconductor pixel. Each signal processing circuit comprises a first processing circuit and a second processing circuit. The first processing circuit has a first shaping circuit. The first shaping circuit shapes the signal such that the time constant of the first processing circuit is a first time constant and outputs a value of the shaped signal as a first signal value. The second processing circuit has a second shaping circuit. The second shaping circuit shapes the signal such that the time constant of the second processing circuit is a second time constant and outputs a value of the shaped signal as a second signal value.
[Problem] To provide a novel technology. [Solution] One aspect of the present invention provides an information processing system. This information processing system comprises at least one processor, and the processor is configured to execute each of the following steps by reading a program. In a reception step, input information is received. The input information includes at least one of first input information related to the number of individuals infected with a specific infectious disease and second input information related to weather. In an output step, output information related to the risk of outbreak of the infectious disease is output on the basis of the input information and preset reference information.
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
National University Corporation Shiga University of Medical Science (Japon)
Inventeur(s)
Saito, Takashi
Harada, Michishige
Shirouzu, Mikako
Matsumoto, Takehisa
Idei, Akiko
Inoue, Jun-Ichiro
Yamamoto, Mizuki
Gohda, Jin
Kawaguchi, Yasushi
Ito, Yasushi
Ishigaki, Hirohito
Nakayama, Misako
Kitagawa, Yoshinori
Abrégé
The present invention provides an antibody that binds to an extracellular domain of TMPRSS2, capable of inhibiting beta coronavirus infection of cells, or an antigen-binding fragment thereof, and a composition including the antibody or an antigen-binding fragment thereof.
An ultrasonic wave generation device (10) comprises an ultrasonic wave generation source (11), an ultrasonic wave focusing part (12), and a waveguide (13). The ultrasonic wave focusing part (12) has a first reflection surface (21) that reflects ultrasonic waves generated by the ultrasonic wave generation source (11), and a second reflection surface (22) that reflects the ultrasonic waves reflected by the first reflection surface (21). The ultrasonic wave generation source (11) generates ultrasonic waves of longitudinal waves. The ultrasonic wave generation device (10) is configured such that the ultrasonic waves of longitudinal waves generated from the ultrasonic wave generation source (11) are converted to transverse waves when reflected by the first reflection surface (21) and move toward a first focal point (F1). The second reflection surface (22) is positioned on a path in which the ultrasonic waves converted to transverse waves by the first reflection surface (21) move toward the first focal point (F1). The ultrasonic wave generation device (10) is configured such that the ultrasonic waves converted to transverse waves by the first reflection surface (21) are reflected by the second reflection surface (22) while remaining as transverse waves and are introduced into the waveguide (13).
H04R 1/34 - Dispositions pour obtenir la fréquence désirée ou les caractéristiques directionnelles pour obtenir la caractéristique directionnelle désirée uniquement en utilisant un seul transducteur avec des moyens réfléchissant, diffractant, dirigeant ou guidant des sons
Provided is a method for evaluating the activity/reactivity of an active/reactive site of a protein, the evaluation method comprising: a labeling step for labeling a protein with an activity-based labeling molecule; and a detection step for detecting, in a solution containing a single molecule of the labeled protein, the activity-based labeling molecule with which the protein is labeled, using an enzymatic reaction of a reporter enzyme that modifies the activity-based labeling molecule. The activity-based labeling molecule is a molecule that reacts with an active/reactive site of the protein and forms a covalent bond with the protein or the active/reactive site thereof after the reaction. The labeling step includes bringing the activity-based labeling molecule into contact with the protein.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
6.
PHASE DISTRIBUTION MEASUREMENT DEVICE, PHASE DISTRIBUTION MEASUREMENT METHOD, AND MACHINE LEARNING METHOD
The present invention provides a phase distribution measurement method that utilizes AI and that makes it possible to perform high-speed processing with high accuracy. The present invention comprises: a diffusion plate that diffuses incident light; a light-receiving device that receives light which has passed through the diffusion plate; and a reconstruction processing unit that estimates the phase distribution of the incident light on the incident surface of the diffusion plate on the basis of the intensity distribution of the received light.
The purpose of the present invention is to realize high resolution corresponding to a high number of optical divisions. This displacement measuring apparatus is provided with: a laser light source; a reuse-type multiple diffraction optical system that acquires diffracted light by causing light-source light emitted from the laser light source to enter a diffraction element as illumination light, and causes the diffracted light from the diffraction element to enter the diffraction element again as illumination light to obtain diffracted light; a frequency modulator that is incorporated in the optical path of the multiple diffraction optical system and performs frequency modulation on the diffracted light; an optical splitter that splits output light including diffracted light corresponding to a multiple modulation component formed as a result of passing through, a plurality of times, the frequency modulator incorporated in the optical path of the multiple diffraction optical system; and a phase detection device that extracts phase information related to the multiple modulation component from the output light split by the optical splitter.
G01D 5/347 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c.-à-d. utilisant de la lumière infrarouge, visible ou ultraviolette avec atténuation ou obturation complète ou partielle des rayons lumineux les rayons lumineux étant détectés par des cellules photo-électriques en utilisant le déplacement d'échelles de codage
8.
EPIGENETICS-ASSOCIATED PROTEIN DECOMPOSITION TECHNOLOGY
The purpose of the present invention is to provide molecules that induce, in cells, the decomposition of proteins associated with epigenetic modification, particularly enzymes (e.g. DNA methyltransferase) that catalyze methylation of nucleic acids. More specifically, the purpose of the present invention is to provide a compound represented by formula (I) or a salt thereof, or a solvate or a hydrate of the same. [In formula (I), A is a double-stranded nucleic acid and includes, in one strand, at least one 5'-CpG-3' sequence in which the 5-position of cytosine (C) has been methylated, the C of the 3'-GpC-5' that is complementary to said 5'-CpG-3' may be a modified base for covalently bonding DNMT1 to A, L is a hydrocarbon that may include oxygen, sulfur, phosphorus, or nitrogen, and B is a ligand molecule of an E3 ubiquitin ligase.]
[Problem] To provide a program, an information processing method, an information processing system, and the like with which it is possible to detect HFpEF early. [Solution] According to one aspect of the present invention, there is provided a program configured to cause a computer to execute an acquisition step, a calculation step, and an output step. In the acquisition step, first electrocardiogram data for a first subject is acquired. In the calculation step, an index corresponding to HFpEF, which is one of the phenotypes of heart failure classified by the left ventricular ejection fraction, and an index corresponding to the expected value of the left ventricular ejection fraction are calculated on the basis of the first electrocardiogram data and reference information. The reference information indicates the relationship between second electrocardiogram data for a second subject and the indexes. In the output step, the calculated indexes are outputted. The index corresponding to HFpEF is at least one from among the probability that HFpEF has developed, an expected value calculated from the probability, and information obtained by scaling the expected value to a prescribed range.
The present disclosure relates to a reducing agent for synthesizing a nitrogen-containing compound, the reducing agent containing an electron supplying site and a proton accepting site that is bonded to the electron supplying site.
The present invention improves analysis accuracy in analyzing a document that includes text information describing a substance. A processing method according to the present invention includes: a first output step for outputting a first distributed representation based on structure information pertaining to a substance having a substance name included in a document; a second output step for outputting a second distributed representation based on text information describing a substance having a substance name included in the document; and a training step for training a model by using the first distributed representation and the second distributed representation.
G06F 40/216 - Analyse syntaxique utilisant des méthodes statistiques
G06F 16/383 - Recherche caractérisée par l’utilisation de métadonnées, p. ex. de métadonnées ne provenant pas du contenu ou de métadonnées générées manuellement utilisant des métadonnées provenant automatiquement du contenu
G06F 18/213 - Extraction de caractéristiques, p. ex. en transformant l'espace des caractéristiquesSynthétisationsMappages, p. ex. procédés de sous-espace
G06N 3/088 - Apprentissage non supervisé, p. ex. apprentissage compétitif
Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.
An ultrasonic wave generation device (10) comprises an ultrasonic wave generation source (11), an ultrasonic wave convergence unit (12), and a waveguide (13). The ultrasonic wave convergence unit (12) includes a reflection unit (21) that has a reflection surface (23) which reflects ultrasonic waves generated by the ultrasonic wave generation source (11) and a connection unit (22) that connects the reflection unit (21) to the waveguide (13). The ultrasonic wave generation source (11) generates longitudinal ultrasonic waves. The ultrasonic wave generation device (10) is configured such that longitudinal ultrasonic waves generated by the ultrasonic wave generation source (11) are transformed into transverse waves upon reflection on the reflection surface (23) and are converged toward the connection unit (22).
H04R 1/34 - Dispositions pour obtenir la fréquence désirée ou les caractéristiques directionnelles pour obtenir la caractéristique directionnelle désirée uniquement en utilisant un seul transducteur avec des moyens réfléchissant, diffractant, dirigeant ou guidant des sons
[Problem] Changing the rearing environment of fish from freshwater to saltwater or from saltwater to freshwater requires fish to quickly adapt to the new environment. Therefore, there has been a need for an evaluation method for evaluating in advance whether fish prior to changing the rearing environment have the ability to adapt to the new environment. [Solution] A method for evaluating the saltwater adaptability of fish that includes a step for examining the expression of a gene of the fish, wherein the gene is a control factor of an ion transporter participating in saltwater adaptation and/or a control factor of an ion transporter participating in freshwater adaptation.
A01K 61/95 - Triage, classement, comptage ou marquage des animaux vivants, p. ex. identification de leur sexe spécialement adaptés aux poissons
C12N 15/12 - Gènes codant pour des protéines animales
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
15.
PROPULSION DEVICE, ROCKET, ARTIFICIAL SATELLITE, AND SPACE PROBE
This propulsion device generates a propulsive force by a combustion reaction, and includes: a combustion chamber, and a metal fuel supply device. The combustion chamber forms a combustion space inside of which it is possible to generate a combustion reaction. The metal fuel supply device is configured to supply a metal fuel to the combustion space. The supplied metal fuel is configured to extend in the combustion space, cause a combustion reaction, and vibrate during the combustion reaction as a result of theoperation of at least a part of the propulsion device.
F02K 9/72 - Moteurs-fusées, c.-à-d. ensembles fonctionnels portant à la fois le combustible et son oxydantLeur commande utilisant des propergols liquides et solides, c.-à-d. ensembles fonctionnels de moteurs-fusées hybrides
16.
ANTIBODY HAVING DOMAIN HAVING MODIFIED ISOELECTRIC POINT
The purpose of the present invention is to provide an antibody capable of achieving high detection sensitivity in an immunochromatography method. The present invention provides a polypeptide including a protein domain having an antigen binding site and a protein domain having no antigen binding site, wherein the theoretical isoelectric point (pI) of the protein domain having an antigen binding site is equal to or less than the theoretical isoelectric point (pI) of the protein domain having no antigen binding site.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
17.
METHOD FOR PRODUCING PHOSPHITE/PHOSPHATE ESTER AND PHOSPHONYLATION/PHOSPHORYLATION AGENT
[Problem] To provide a method for producing a phosphite/phosphate ester with which it is possible to produce a phosphite/phosphate ester efficiently by a small amount of catalyst, and a phosphonylation/phosphorylation agent that can be used in said method. [Solution] A method for producing a phosphite/phosphate ester is provided according to one embodiment of the present invention. This production method comprises a step for preparing a catalyst, an alcohol, and phosphonylation/phosphorylation agent and a step for reacting the alcohol with the phosphonylation/phosphorylation agent in the presence of the catalyst to obtain a phosphite/phosphate ester. When the phosphonylation/phosphorylation agent is a phosphorylation agent, a metal-containing catalyst functioning as a Lewis acid is used as the catalyst. When the phosphonylation/phosphorylation agent is a phosphorylation agent or a phosphonylation agent, an organic catalyst functioning as a base is used as the catalyst.
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
B01J 31/04 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques contenant des acides carboxyliques ou leurs sels
C07F 9/145 - Esters des acides phosphoreux avec des composés hydroxyarylés
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
[Problem] To provide a microneedle patch having porous microneedles capable of collecting and storing interstitial fluid, and a method for manufacturing the microneedle patch. [Solution] Provided is a microneedle patch with porous microneedles and an absorbent material capable of absorbing interstitial fluid, wherein the microneedles and the absorbent material are integrated.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
G01N 1/10 - Dispositifs pour prélever des échantillons à l'état liquide ou fluide
19.
CATALYST FOR AMMONIA SYNTHESIS AND METHOD FOR PRODUCING AMMONIA
Provided is a novel catalyst for ammonia synthesis and a method for producing ammonia that uses the catalyst. Provided are: a catalyst for ammonia synthesis that comprises an oxo complex that includes a PCP-type pincer ligand; and a method for producing ammonia that involves performing an ammonia synthesis reaction using nitrogen, a proton source, a reducing agent, and the catalyst for ammonia synthesis.
It is an object of the present invention to provide a pyrrole imidazole polyamide (PIPA), which suppresses the expression of cytokines essential for activation of immune response, in particular, the expression of type I IFN, at a transcription stage. More specifically, the present invention relates to a PIPA that specifically binds to the binding region of an IRF (IFN regulatory factor) family transcription factor. Specifically, the present PIPA is a PIPA that binds to 5′-GAAAGTG-3 (SEQ ID No: 1) or a modified sequence thereof, 5′-GAAAG-3′ (SEQ ID No: 9) or a modified sequence thereof, 5′-GAAAA-3′ (SEQ ID No: 15) or a modified sequence thereof, or 5′-GAAAC-3′ (SEQ ID No: 21) or a modified sequence thereof.
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
21.
TIME-STRETCH SPECTROSCOPY DEVICE AND TIME-STRETCH SPECTROSCOPY METHOD
Provided is a time-stretch spectroscopy device capable of restoring an original spectrum without using a high-speed modulation system or reception system even if temporally adjacent pulses overlap after stretching. This time-stretch spectroscopy device comprises: an optical modulator that performs intensity modulation in pulse units on a group of measurement light pulses, which are obtained by irradiating a measurement object having characteristics relating to light transmittance or reflectance with a group of light pulses; a pulse stretcher that performs time stretching on the group of measurement light pulses; and a signal processing device that, with the assumption that the measurement light pulses are sparse as data, performs a reconfiguration estimating pulse signal wavelength components corresponding to the stretched light pulses, which are obtained by individually time stretching the group of measurement light pulses, in light of a superimposition signal synthesized such that a temporal overlap occurs after the time stretching.
G01J 11/00 - Mesure des caractéristiques d'impulsions lumineuses individuelles ou de trains d'impulsions lumineuses
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 21/27 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
22.
AN AI-BASED METHOD AND DEVICE FOR BIOFLUID CLASSIFICATION USING DRYING DROPLET PATTERNS
A method for biofluids classification executed by a classification device comprising a processor, the method causing the processor to: a) acquire at least one microscopy image of biofluid deposited on a predetermined solid surface, b) execute a predetermined classification processing operation based on the acquired microscopy image; and c) output a classification result corresponding to the executed classification processing.
The present invention provides a nucleic acid for transfection in which a nucleic acid targeted for introduction into a cell and a cell membrane-permeable group are linked together, the cell membrane-permeable group contains a perfluoroalkyl group having 2 to 10 carbons, and the perfluoroalkyl group may have one to five ether-bonded oxygen atoms between the carbon atoms, and also provides a nucleic acid transfection method that involves bringing the nucleic acid for transfection into contact with a cell to introduce the nucleic acid into the cell.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
24.
GAS COMPONENT DETECTION DEVICE AND GAS COMPONENT MEASUREMENT SYSTEM
Provided is a gas component inspection device capable of measuring the concentration of a gas component contained in an air flow with higher accuracy. A gas component detection device for detecting a prescribed gas component contained in a gas includes: a gas introduction port for introducing a gas into a container; and a plurality of gas detection elements arranged in the container and exposed to the gas discharged from the gas introduction port, wherein the plurality of gas detection elements are arranged at intervals at positions where distances from the gas introduction port are made different from each other. The concentration of the gas component in the gas is determined by arithmetic processing on the basis of output signals from the plurality of gas detection elements.
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
25.
NON-REPLICATING BOVINE INFECTIOUS LYMPHOMA VIRUS (BLV) AND CELLS FOR PRODUCING SAME
An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.
A capacitance sensor is capable of correcting an object detection result irrespective of changes in ambient air conditions and capable of simplifying a configuration for the correction. The capacitance sensor includes a detection sensor including a detection electrode and configured to output a sensed value representing a capacitance created between the detection electrode and an object such as a human worker. The sensor includes a reference electrode provided to face the detection electrode and coupled to a reference potential via a switch. The sensor also includes a processing device that controls opening/closing of the switch to transition between a first state in which the reference electrode is opened and a second state in which the reference electrode is coupled to the reference potential.
G01D 5/24 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension en faisant varier la capacité
G01R 27/26 - Mesure de l'inductance ou de la capacitanceMesure du facteur de qualité, p. ex. en utilisant la méthode par résonanceMesure de facteur de pertesMesure des constantes diélectriques
An antenna array with multiple testing antenna elements 14 that can test a device-under-test 12 in a practical way, thus allowing for a multitude of efficiencies (e.g. time saving, less errors, less mechanical components, etc.). At least a portion of each of the planer antenna elements 14 of an antenna array may be formed between an upper ground plane 16 and a lower ground plane 18, which may enhance electromagnetic characteristics. In other configurations, defective ground structures {22, 23} may be formed in the upper ground plane 16 and/or a lower ground plane 18, which may enhance electromagnetic characteristics. In some configurations, the defective ground structure {22, 23} may be formed above a pole portion 14P of at least one planer antenna element 14. In other configurations, the defective ground structure {22, 23} is formed between the pole portions 14P of two adjacent planer antenna elements 14.
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.
The present invention provides a transcranial magnetic stimulation coil capable of generating an electric field in the deep part of the brain. A wearable device 2 is configured in a substantially spherical shape having an inner accommodation space capable of accommodating the head of a subject. A part of the wearable device 2 is an opening portion 21 through which the head can pass, so that the wearable device can be worn on the head via the opening portion 21. A first winding portion 11 is disposed on a right side surface portion 23, and a second winding portion 12 is disposed on a left side surface portion 24. Conducting wires constituting the first winding portion 11 and conducting wires constituting the second winding portion 12 are disposed on a top surface portion 22 and a back surface portion 25 as well. The conducting wires disposed on the top surface 22 are parallel to each other.
A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
THE UNIVERSITY OF TOKYO (Japon)
Inventeur(s)
Okano Makoto
Takenaka Mitsuru
Tang Rui
Abrégé
A photoelectric conversion element (100) according to the present embodiment comprises a first laminate (10) and a first optical waveguide (20). The first laminate (10) includes: a first impurity semiconductor provided in an upper section in the lamination direction; a second impurity semiconductor that has a conductivity type which is different from that of the first impurity semiconductor and that is provided in a lower section in the lamination direction; and a first intrinsic semiconductor sandwiched between the first impurity semiconductor and the second impurity semiconductor in the lamination direction. When viewed from the lamination direction, the length of a first side (S1) of the first intrinsic semiconductor of the first laminate (10) is longer than the length of a second side (S2) that intersects the first side. The first optical waveguide (20) is connected to a first lateral surface to which the first side (S1) of the first laminate (10) belongs.
H10F 30/223 - Dispositifs individuels à semi-conducteurs sensibles au rayonnement dans lesquels le rayonnement commande le flux de courant à travers les dispositifs, p. ex. photodétecteurs les dispositifs ayant des barrières de potentiel, p. ex. phototransistors les dispositifs étant sensibles au rayonnement infrarouge, visible ou ultraviolet les dispositifs ayant une seule barrière de potentiel, p. ex. photodiodes la barrière de potentiel étant du type PIN
An antiprotozoal agent targeting a transcription factor is disclosed. A pyrrole-imidazole polyamide (PIPA) specifically binding to a binding region of a protozoa transcription factor is disclosed. A method for producing the PIPA, and a protozoan transcription factor inhibitor that includes the PIPA are disclosed. Also disclosed is a method for treating or preventing a disease caused by a protozoon by inhibiting a protozoan morphological change using a PIPA that can function as a competitive pseudo-transcription factor specifically binding to a binding region for a protozoan transcription factor.
A gate drive device operates on two sides, a high side and a low side, and drives a gate of a power transistor. The gate drive device includes: a control device provided in pair to constitute the two sides, and configured to output a switching signal of three or more levels including a high level, a low level, and one or more intermediate levels between the high level and the low level according to a received control signal; and a switching element provided in pair corresponding to the control device, and configured to output, to the gate of the power transistor, a voltage corresponding to a level of the switching signal received from the control device.
H03K 17/687 - Commutation ou ouverture de porte électronique, c.-à-d. par d'autres moyens que la fermeture et l'ouverture de contacts caractérisée par l'utilisation de composants spécifiés par l'utilisation, comme éléments actifs, de dispositifs à semi-conducteurs les dispositifs étant des transistors à effet de champ
H03K 17/567 - Circuits caractérisés par l'utilisation d'au moins deux types de dispositifs à semi-conducteurs, p. ex. BIMOS, dispositifs composites tels que IGBT
33.
SELECTIVE INTRACELLULAR DELIVERY OF PROTEIN IN CELLS WITH NANOCARRIERS SENSING CATHEPSIN B ACTIVITY
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
34.
DIFFRACTIVE OPTICAL ELEMENT AND METHOD FOR MANUFACTURING DIFFRACTIVE OPTICAL ELEMENT
Provided are a diffractive optical element that is thin and highly amenable to mass production, and that has high light condensing performance and is applicable to fine pixel pitch, and a method for manufacturing the diffractive optical element. The diffractive optical element causes diffraction of incident light in a wavelength range of 410-1,100 nm, and comprises: a substrate that transmits incident light; and a light shielding resin layer that forms unevenness on the main surface of the substrate and forms a diffraction pattern that is substantially concentric when viewed in a direction orthogonal to the main surface of the substrate, the light shielding resin layer being formed by a curable resin composition and shielding at least some wavelengths of light in the incident light.
The present invention provides a pharmaceutical composition for the treatment or prevention of a disease(s) caused by reduction or deficiency in 5-taurinomethyluridine (τm5U) modification of mitochondrial tRNA, the composition comprising mitochondrial tRNA translation optimization 1 (MTO1) or nucleic acid encoding MTO1, wherein MTO1 is administered to a patient in an excess amount, or MTO1 is overexpressed in a patient to whom the nucleic acid has been administered.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07H 19/067 - Radicaux pyrimidine avec un ribosyle comme radical saccharide
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A detection device includes a first optical sensor, a second optical sensor disposed at a predetermined distance from the first optical sensor, a light source that emits light to be detected by the first optical sensor and the second optical sensor facing a living body tissue including a blood vessel, and a processor that calculates a pulse wave velocity of the blood vessel based on a time-series variation of an output of the first optical sensor, a time-series variation of an output of the second optical sensor, and the predetermined distance.
This sensor element is for selectively recognizing molecules and comprises: a detection part having a molecule recognition site and a hydrocarbon chain R1in the same molecule; and a semiconductor part having a hydrocarbon chain R2, wherein the semiconductor part changes electrical conduction characteristics in accordance with whether said molecule is attached or detached in the detection part.
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
C08L 65/00 - Compositions contenant des composés macromoléculaires obtenus par des réactions créant une liaison carbone-carbone dans la chaîne principaleCompositions contenant des dérivés de tels polymères
C08L 79/00 - Compositions contenant des composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant uniquement de l'azote, avec ou sans oxygène ou carbone, non prévues dans les groupes
The present invention provides a polymeric complex comprising a protein and a block copolymer represented by the following formula (1):
The present invention provides a polymeric complex comprising a protein and a block copolymer represented by the following formula (1):
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A crystal according to the present invention is formed as a result of the accumulation of a host-guest complex constituted by: a host molecule that has an opening and an internal space and that has a three-fold rotation axis, a four-fold rotation axis, or a six-fold rotation axis; and a guest molecule accommodated in the internal space of the host molecule. When visualizing a rectangular parallelepiped in which the lengths of three sides are a, b, and c (where a ≥ b ≥ c) can accommodate the crystal, a would be 1 mm or more, b would be 1 mm or more, and c would be 0.05 mm or more in a rectangular parallelepiped having the minimum capacity. A method for producing a crystal according to the present invention is characterized in that a solution containing host molecules and guest molecules is left to stand.
C07C 13/64 - Hydrocarbures polycycliques ou leurs dérivés hydrocarbonés acycliques à cycles condensés à plus de trois cycles condensés à système cyclique ponté
C07C 7/20 - Emploi d'additifs, p. ex. pour la stabilisation
The invention relates to novel systems for nucleic acid engineering utilizing components of IS110 family transposons including a modified bridgeRNA. The bridgeRNA, which targets donor and target sequence sites or multiple donor site sequences for polynucleotide recombination reactions, is modified within the handshake guide (HSGs) sequences, one or more scaffold sequences, or both the HSG sequences and one or more scaffold sequences. In certain aspects, the application relates to the utilization and reprogramming of the modified bridgeRNA to direct IS110 transposases to integrate sequences at predetermined sites. Programmable insertion, excisive recombination, and/or inversion enables integration or transposition of any polynucleotide sequence encoding a donor site or target site recognized by the IS110 transposase into any other polynucleotide sequence containing a target site sequence or donor site sequence, respectively, or between two donor site sequences using an IS110 transposase and modified bridgeRNA.
The present invention provides a plant cultivation method that makes it possible to increase plant growth speed by irradiation with high-illuminance light while suppressing the occurrence of a photoinhibition or photoprotection reaction in the plant. Provided is a dicotyledon plant cultivation method in which light 3 of a wavelength in a red region that is included in the wavelength band for the absorption peak of chlorophyll a is radiated toward a dicotyledon plant 4. The light 3 is emitted from a laser light source 1, does not include light of a wavelength outside the wavelength band for the absorption peak of the chlorophyll a, and, at the point of arrival at the dicotyledon plant 4, has a photon flux density (PPFD) which is a predetermined value or greater.
An antibody which binds to DLL3 protein, composition containing the antibody, and uses thereof are disclosed. The antibody recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. Also disclosed are a pharmaceutical composition, for example, an anticancer agent, containing the antibody of the present invention as an active ingredient. Further disclosed is a method for diagnosing cancer using the antibody and a diagnostic drug for cancer containing the antibody.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
According to an aspect, a detection device includes: a first detection circuit including a first photodiode sensitive to first light and a second photodiode sensitive to second light; and a second detection circuit including a third photodiode sensitive to third light. The first photodiode and the second photodiode are coupled in series and in opposite directions to form a first detection element. One end side of the first detection element is coupled to a first signal line via a first transistor. Another end side of the first detection element is configured to be supplied with a first drive signal. A cathode of the third photodiode is coupled to a second signal line via a second transistor. An anode of the third photodiode is configured to be supplied with a second drive signal.
As a technique that can be used for cancer immunotherapy of adult T-cell leukemia (ATL), provided is a pharmaceutical composition for treatment or prevention of adult T-cell leukemia, the pharmaceutical composition containing a peptide consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 68.
[Abstract] [Problem] To provide a novel semiconductor device and the like. [Solution] This semiconductor device comprises a board and a semiconductor chip provided in the vertical direction of the board, wherein the semiconductor chip includes a processor or a memory, a communication coil performs magnetic field coupling communication with another communication coil provided at a location away from the board and the semiconductor chip, the communication coil transmits information inputted from the semiconductor chip or outputs received information to the semiconductor chip, the communication coil comprises a winding at least partially formed inside the board, and the central axis direction of the winding is different from the vertical direction. [Selected drawing] FIG. 2
MITSUBISHI HEAVY INDUSTRIES MACHINERY SYSTEMS, LTD. (Japon)
THE UNIVERSITY OF TOKYO (Japon)
Inventeur(s)
Shimizu, Takaya
Iehara, Masato
Kamijo, Shunsuke
Lee, Jinho
Abrégé
A three-dimensional data estimation device (100) comprises: an acquisition unit that acquires, as input information, three-dimensional optical distance measurement data (D1) detected for a detection target; and an estimation unit that estimates three-dimensional radio wave distance measurement data (D2), which corresponds to the input information, by means of a learning model obtained by machine learning of a correspondence relationship between the three-dimensional optical distance measurement data detected for the detection target and three-dimensional radio wave distance measurement data detected for the detection target.
The present invention provides a method for culturing human pancreatic islet cells, the method comprising culturing human pluripotent stem cell-derived pancreatic islet cells in a medium containing B27 or ITS-X.
Provided is a computer program, an information processing method, and a system, whereby work in a plurality of farming fields can be efficiently carried out. This computer program, information processing method, and system acquire farming field information pertaining to a plurality of farming fields and machine information pertaining to a plurality of work machines (10, 10a-10c), and determine, on the basis of the acquired farming field information and machine information, the allocation of the work machines (10, 10a-10c) to the farming fields. Preferably, if an abnormality has occurred in one of the work machines or if a delay has occurred in the work of one of the work machines, the allocation of the work machines to the farming fields is recalculated.
In sonic embodiments, an optimization method implemented by a computational subnetwork is provided. The method may include initializing, by a state node of the computational subnetwork, a state vector; injecting, by a context node of the computational subnetwork, amplitude heterogeneity errors to the state vector, the injecting avoiding a solution converging on a local minimum point; and selectively controlling, by an input node of the computational subnetwork, the amplitude heterogeneity error by fixing states of high error states for durations of corresponding refractory periods.
G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
50.
PARASPORIN EXPRESSION VECTOR AND PHARMACEUTICAL COMPOSITION
There are provided an expression vector into which a gene encoding parasporin (hereinafter abbreviated as “PS”) is inserted that can realize a pharmaceutical composition applicable to the treatment of cancer; a cell into which the expression vector is introduced; a method for expressing PS, a pharmaceutical composition; and a transformant. The expression vector contains a gene encoding parasporin. The expression vector includes viral vectors into which the gene is inserted, and the viral vectors express a PS protein. The gene encoding a PS protein has the full length or a part of PS gene, which includes PS-like genes encoding proteins that have no hemolytic properties against red blood cells and that exhibit selectively cytotoxicity to cancer cells among the Cry proteins produced by Bt bacteria and/or Bt related bacteria.
The present invention addresses the problem of providing a novel method for inexpensively producing 5-hydroxy-L-lysine with high yield and at low cost. As a solution for the problem, the present invention provides: a novel L-lysine position-5 hydroxylase; an enzyme agent composition for producing 5-hydroxy-L-lysine, the composition containing the hydroxylase; and a method for producing 5-hydroxy-L-lysine using the enzyme agent composition.
Provided is a laser oscillation method in which a SLM is disposed on a resonance path and a laser medium is irradiated with excitation light, whereby laser light is caused to oscillate in the resonance path, the laser oscillation method comprising: a data acquisition step of irradiating the laser medium with the excitation light and acquiring data related to the current oscillation; an estimation step of estimating, using an estimation program for outputting a parameter related to a phase pattern displayed on the SLM in response to the entry of the data related to the oscillation and information indicating a target oscillation state, a parameter related to the phase pattern according to the target oscillation state and the data related to the current oscillation acquired in the data acquisition step; and a control step of controlling the phase pattern displayed on the SLM on the basis of the parameter estimated in the estimation step.
H01S 3/105 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de la position relative ou des propriétés réfléchissantes des réflecteurs de la cavité
G02F 1/01 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur
53.
SYSTEM FOR PRODUCING CALCIUM CARBONATE, METHOD FOR PRODUCING CALCIUM CARBONATE, METHOD FOR PRODUCING SODIUM CARBONATE, METHOD FOR PRODUCING GEL CONTAINING SILICON OXIDE, METHOD FOR TREATING CONCRETE MATERIAL, AND METHOD FOR FIXING CARBON DIOXIDE
A system for producing calcium carbonate according to an embodiment includes: a base treatment device in which a concrete material is treated with a base to precipitate calcium hydroxide; and a calcium-hydroxide carbonation device in which the calcium hydroxide is carbonated to yield calcium carbonate.
Provided are an inspection device including a porous microneedle that has high mechanical strength and can allow rapid sampling of an interstitial fluid or the like by capillary force, and a process for manufacturing the microneedle.
Provided are an inspection device including a porous microneedle that has high mechanical strength and can allow rapid sampling of an interstitial fluid or the like by capillary force, and a process for manufacturing the microneedle.
An inspection device comprises: a porous microneedle; and a paper substrate sensor having at least one measurement region, in which the microneedle is formed of microspheres of a biodegradable material.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
A mastication detection device comprising: a sensor that is mounted on a lower jaw side surface; and a mastication detection unit that executes, on the basis of a dead time setting and with hysteresis, detection of a positive-slope zero crossing from a detection signal from the sensor, executes a comparison of the detection signal from the sensor with a threshold value for detecting mastication activity when a positive-slope zero crossing is detected, and detects, on the basis of the comparison result, whether a continuous activity performed by a person wearing the sensor is mastication activity.
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61C 19/04 - Instruments de mesure spécialement adaptés à la technique dentaire
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A seismic exploration method includes: causing a seismic source device disposed in a subsurface to generate a vibration; and acquiring, by a signal acquisition device, a vibration signal based on the vibration generated by the seismic source device. The seismic source device includes rotating bodies that are eccentric, and each rotates about a rotation shaft, and a drive unit that generates vibration by rotating the rotating bodies.
With this flood prediction method, a computer system 1 creates an observed inundation map 64 on the basis of observation data before and after past flood events in a given region, creates a simulated inundation map 65 by performing physical flood simulation using estimated precipitation data, estimated runoff data, and river topography data related to the flood events as input data, generates a neural network model for predicting an inundation area on the basis of elevation data 62 and precipitation data 63 by machine learning using the photographed image inundation map and the simulated inundation map as training data, and creates a prediction flood map 60 for enabling identification of an inundation area in a flood prediction target area through input of elevation data and precipitation data related to the flood prediction target area into the trained neural network model.
G08B 31/00 - Systèmes d'alarme à prédiction caractérisés par une extrapolation ou un autre type de calcul utilisant des données historiques mises à jour
58.
ACTUATOR ANGLE ESTIMATION DEVICE AND ACTUATOR ANGLE ESTIMATION METHOD
An actuator angle estimation device 10 is an actuator bend angle estimation device 10 comprising a tube member 24 that has a first chamber 25A and a second chamber 25B which are spaced apart from each other, disposed along the axial direction, and arranged parallel to each other. The actuator bend angle estimation device 10 estimates the bend angle of an elongated actuator body section 22 that is bent as a result of one side of a tube wall being shortened in the axial direction in response to a rise in the internal pressure of the first chamber 25A. The actuator bend angle estimation device 10 additionally comprises: a fluid supply unit that supplies a fluid to the first chamber 25A; a pressure sensor 62 that acquires the internal pressure of the second chamber 25B; and an angle estimation unit that estimates the bend angle of the actuator body 22 on the basis of the internal pressure of the second chamber 25B, which is in a sealed state, as acquired by the pressure sensor 62.
F15B 15/10 - Dispositifs actionnés par fluides pour déplacer un organe d'une position à une autreTransmission associée à ces dispositifs caractérisés par la structure de l'ensemble moteur le moteur étant du type à diaphragme
G01B 21/22 - Dispositions pour la mesure ou leurs détails, où la technique de mesure n'est pas couverte par les autres groupes de la présente sous-classe, est non spécifiée ou est non significative pour mesurer des angles ou des conicitésDispositions pour la mesure ou leurs détails, où la technique de mesure n'est pas couverte par les autres groupes de la présente sous-classe, est non spécifiée ou est non significative pour tester l'alignement des axes
59.
OPTICAL DEVICE, RECEPTION MODULE, AND COHERENT RECEIVER
Provided are an optical device, a reception module, and a coherent receiver which are capable of performing spatial mode and polarization separation, and are advantageous for miniaturization. A reception module 13 has a mode separation multiplexer 14 and a light receiving element array 15. The mode separation multiplexer 14 has six metasurfaces 21A to 21F arranged apart from each other in a plurality of stages, and receives signal light S and local light Lo subjected to spatial mode multiplexing and polarization multiplexing. Through the metasurfaces 21A to 21F, a plurality of divided signal light components are generated for each signal light component of the signal light S, the local light Lo is divided into a plurality of divided local light beams, and interference light in which the divided signal light components and the divided local light beams are caused to interfere with each other is generated. Through the metasurfaces 21A to 21F, a phase is controlled so that, at the output positions of the divided signal light components for each signal light component, the divided signal light components and the divided local light beams interfere with each other in different phase differences. For each signal light component, the complex amplitude of the signal light component is obtained from each interference light.
G02B 1/02 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de cristaux, p. ex. sel gemme, semi-conducteurs
[Problem] The present invention addresses the problem of providing a novel technique capable of efficiently preparing cell clusters, such as spheroids and organoids, in a desired shape. [Solution] It has been found that a large amount of cell clusters, such as spheroids, having a fine shape can be prepared by using a culture substrate having a specific modified surface and obtained by laminating, on a substrate, a block layer that hinders adhesion to adherent cells, and then preferably patterning and modifying cell adhesion molecules having a photodegradable linker cleaved by irradiation with light.
The present disclosure pertains to: a composition for preventing or treating colorectal cancer, which contains an IgA antibody or an antigen-binding fragment thereof; and a method for preventing or treating colorectal cancer using a composition containing an IgA antibody or an antigen-binding fragment thereof.
This anti-inflammatory or aging-suppressing composition contains extracellular vesicles derived from a plant of the family Apiaceae, Lamiaceae, Theaceae, Selaginellaceae, Brassicaceae, Asteraceae, Amaranthaceae, Amaryllidaceae, Fabaceae, Cucurbitaceae, Zingiberaceae, Polygonaceae, Dioscoraceae, Vitaceae, Rosaceae, Solanaceae, Ericaceae, Lythraceae or Rutaceae, a mushroom or a microalga.
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
A61K 36/906 - Zingiberaceae (famille du gingembre)
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61Q 5/00 - Préparations pour les soins des cheveux
A61Q 19/00 - Préparations pour les soins de la peau
Kanagawa Institute of Industrial Science and Technology (Japon)
Inventeur(s)
Sato, Moritoshi
Kuwasaki, Yuto
Nakajima, Takahiro
Abrégé
The present invention provides a set of Affibody and photoreceptor protein, wherein the Affibody and the photoreceptor protein form a complex in a manner dependent on light at a wavelength of 600 to 750 nm.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Shoji, Tetsuya
Sakuma, Noritsugu
Kinoshita, Akihito
Fukushima, Tetsuya
Akai, Hisazumi
Okumura, Haruki
Sakurai, Masahiro
Miyake, Takashi
Fukazawa, Taro
Tamai, Keiichi
Abrégé
A Sm—Fe—N-based magnetic material in which the use amount of Sm is further reduced while enhancing the saturation magnetization, and a production method thereof, are provided. The present disclosure discloses a Sm—Fe—N-based magnetic material including a main phase having a crystal structure of at least either Th2Zn17 type or Th2Ni17 type, wherein the main phase is represented by the molar ratio formula (Sm(1-x-y-z)LaxCeyR1z)2(Fe(1-p-q-s)CopNiqMs)17Nh, where R1 is one or more rare earth elements other than Sm, La and Ce, and Zr, and M is one or more elements other than Fe, Co, Ni and rare earth elements, and an unavoidable impurity element, and 0.09≤x≤0.31, 0.24≤y≤0.60, 0.51≤x+y≤0.75, 0≤z≤0.10, 0≤p+q≤0.10, 0≤s≤0.10, and 2.9≤h≤3.1 are satisfied, and a production method thereof.
H01F 1/059 - Alliages caractérisés par leur composition contenant des métaux des terres rares et des métaux de transition magnétiques, p. ex. SmCo5 et des éléments Va, p. ex. Sm2Fe17N2
H01F 1/055 - Alliages caractérisés par leur composition contenant des métaux des terres rares et des métaux de transition magnétiques, p. ex. SmCo5
The purpose of the present disclosure is to suppress the growth of ice on a substrate. The layer according to the present disclosure is no thicker than 1 millimeter and causes thin ice made from arrays of ice nuclei to form on the surface of the layer.
C09K 3/18 - Substances non couvertes ailleurs à appliquer sur des surfaces pour y minimiser l'adhérence de la glace, du brouillard ou de l'eauSubstances antigel ou provoquant le dégel pour application sur des surfaces
C09D 133/00 - Compositions de revêtement à base d'homopolymères ou de copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un seul radical carboxyle, ou ses sels, anhydrides, esters, amides, imides ou nitrilesCompositions de revêtement à base de dérivés de tels polymères
C09D 201/00 - Compositions de revêtement à base de composés macromoléculaires non spécifiés
F25C 1/12 - Production de glace par congélation de l'eau des surfaces refroidies, p. ex. pour former des plaques
66.
NOVEL USAGE OF ONCOLYTIC GENE-MODIFIED MEASLES VIRUS
An object of the present invention is to develop gene-modified measles viruses (rMV-SLAMblind and rMV-V(−)-SLAMblind) that do not recognize SLAM as a tool for a medical treatment for tumors. The present invention provides a pharmaceutical composition for inducing cell-mediated immunity against a tumor cell to subject the tumor cell to medical treatment, the pharmaceutical composition containing an oncolytic gene-modified measles virus, and also provides a method of inducing cell-mediated immunity against a tumor cell remaining in a living body that could not be eliminated even by direct introduction of an oncolytic gene-modified measles virus, or against a tumor cell that has metastasized or recurred, the method including directly introducing an oncolytic gene-modified measles virus into a tumor cell as a medical treatment target to cause cell death.
It is an object of the present invention to provide a method for producing a virus, for use in obtaining viral particles with high purity, and the present method is more efficient than conventional methods. Specifically, the present invention relates to a method for obtaining a virus, comprising a step of treating a virus-containing sample with a surfactant. The surfactant may be one or more selected from the group consisting of an amphoteric surfactant, an anionic surfactant, a cationic surfactant, and a nonionic surfactant. In addition, the method for obtaining a virus according to the present invention may comprise a step of performing tangential flow filtration (TFF) to purify the virus.
The purpose of the present invention is to provide a method for substituting a full-length gene of a non-human mammal with a human ortholog full-length gene with high reproducibility and high efficiency by using a homologous recombination technique. According to the present invention, there is provided a method for the knock-in of a human ortholog full-length gene into a corresponding locus in a human mammal, the method being characterized by using: a first cyclic vector that targets a non-human mammalian ortholog full-length gene in a non-human mammalian ortholog full-length gene locus; and a second cyclic vector that includes a human ortholog full-length gene and a human homologous arm sequence located at each of the 5' end and the 3' end of the human ortholog full-length gene.
An information processing apparatus selects a target sequence variation possessed by a subject and having a risk of being harmful. The information processing apparatus includes a filtering unit that classifies one or more sequence variations specified by sequencing a nucleic acid included in the subject into different categories according to a degree of risk of being harmful on the basis of one or more classification criteria, and a control unit that classifies a base sequence including a sequence variation of which a category to which the sequence variation is to belong is known into each of the categories according to the degree of risk of being harmful on the basis of at least one of the classification criteria, and compares a classification result with the category to which the sequence variation is to belong, an information processing method, and an information processing program.
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Shinkura, Reiko
Mori, Tomoyuki
Tamano, Ryutaro
Dohmae, Naoshi
Hakoshima, Toshio
Abrégé
The present invention relates to an antibody binding to an intestinal bacterium, an antigen-binding fragment thereof, and uses thereof. In addition, the present invention discloses a nucleic acid encoding the antibody or the antigen-binding fragment thereof, an expression vector comprising the nucleic acid, a cell comprising the nucleic acid or the expression vector, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a method for producing the antibody, and a method for treating an inflammatory disease by administering the antibody or the antigen-binding fragment thereof.
The purpose of the present invention is to provide a composition that is superior for practical use with regard to a ligand for activating NKT cells. A liposome agent according to the present invention is characterized by containing a PEGylated liposome, and is also characterized in that: the PEGylated liposome contains an NKT cell ligand and a liposome-constituting lipid; the NKT cell ligand is an α-galactosylceramide, or an analog thereof, that is specifically recognized by an NKT cell receptor on an NKT cell; and the liposome-constituting lipid contains a choline-containing phospholipid, a PEGylated phospholipid, and a cholesterol-based lipid.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 9/1271 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
The present invention provides a production method for an aryl compound that contains a thio group that is substituted with at least one fluorine atom. The present invention is a production method for a fluorinated thio group–containing aryl compound that involves synthesizing a fluorinated thio group–containing aryl compound in which at least one fluorine atom has been introduced into a thio group from a thio group–containing aryl compound represented by general formula (1) (in which A1is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, and R1 is a trityl group, a methoxymethyl group, or a benzoyl group) by means of an oxidation fluorination reaction that uses trichloroisocyanuric acid, an alkali metal fluoride, and potassium bis(trifluoromethanesulfonyl)imide, methanol, or trifluoroacetic acid.
C07C 381/00 - Composés contenant du carbone et du soufre et comportant des groupes fonctionnels non couverts par les groupes
C07C 303/16 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'acides sulfoniques ou de leurs halogénures par oxydation de thiols, de sulfures, d'hydropolysulfures ou de polysulfures, avec formation de groupes sulfo ou halogénosulfonyle
C07C 309/86 - Halogénures d'acides sulfoniques ayant des groupes halogénosulfonyle liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
The present invention addresses the problem of providing a male fish individual having low aggressiveness. The present invention also address the problem of providing a male fish individual having higher growth efficiency. The present invention provides a male fish individual having suppressed functional expression of CYP19a1b (cytochrome P450, family 19, subfamily A, polypeptide 1b).
A wireless communication device includes: a temperature sensor measuring temperature of concrete within sheathing boards contacting therewith, and transmits signals of the temperature sensor by radio; a flange including a bottom surface flushing with a contact surface of an opening being formed in the sheathing boards; an insertion portion in a tapered conical shape protruding to an inside of a formwork from the flange, and holding the temperature sensor; a head portion with a diameter less than that of the flange exposing to an outside of the formwork from the flange, the wireless communication device is integrated with the concrete whereby: the head portion is fixed by means of a fixing tool until the formwork has not been separated; and the insertion portion is held by hardened and contracted concrete after the formwork has been separated.
H04L 67/12 - Protocoles spécialement adaptés aux environnements propriétaires ou de mise en réseau pour un usage spécial, p. ex. les réseaux médicaux, les réseaux de capteurs, les réseaux dans les véhicules ou les réseaux de mesure à distance
The present invention provides a polymeric complex comprising a cytokine and a block copolymer represented by the following formula (1).
The present invention provides a polymeric complex comprising a cytokine and a block copolymer represented by the following formula (1).
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention is a copolymer having a structure represented by a general formula (1) [in the formula, R1 is a fluorine atom, or a perfluoroalkyl group or perfluoroalkoxy group having 1 to 10 carbon atoms which may have —O— between carbon atoms; R2 and R3 each independently represent a hydrogen atom, a halogen atom, an aliphatic hydrocarbon group having 1 to 30 carbon atoms which may have a substituent, or an aryl group which may have a substituent; the R2 and R3 may be linked with each other to form a ring; the aliphatic hydrocarbon group may contain one or more selected from the group consisting of —O—, —Si(CH3)2—, —CO—, and —NH— between carbon atoms; x and y are positive numbers satisfying a relationship of x+y=1; and a filled circle represents a bond].
The present invention is a copolymer having a structure represented by a general formula (1) [in the formula, R1 is a fluorine atom, or a perfluoroalkyl group or perfluoroalkoxy group having 1 to 10 carbon atoms which may have —O— between carbon atoms; R2 and R3 each independently represent a hydrogen atom, a halogen atom, an aliphatic hydrocarbon group having 1 to 30 carbon atoms which may have a substituent, or an aryl group which may have a substituent; the R2 and R3 may be linked with each other to form a ring; the aliphatic hydrocarbon group may contain one or more selected from the group consisting of —O—, —Si(CH3)2—, —CO—, and —NH— between carbon atoms; x and y are positive numbers satisfying a relationship of x+y=1; and a filled circle represents a bond].
The present invention provides a novel flame-retardant material and flame-retardant sheet including anionically modified pulp. A flame-retardant material and a flame-retardant sheet according to the embodiments include anionically modified pulp in which the counter ions of anionic groups include metal ions, wherein the anionically modified pulp contains anionic groups in the amount of 1.1-3.0 mmol/g as measured after converting all anionic groups to acid type.
D06M 13/00 - Traitement des fibres, fils, filés, tissus ou articles fibreux faits de ces matières, avec des composés organiques non macromoléculairesUn tel traitement combiné avec un traitement mécanique
79.
MATERIAL FOR THERMOFORMING AND MOLDED PRODUCT THEREOF
Provided is a material for thermoforming that contains microfibrous cellulose exhibiting thermoformability. A material for thermoforming according to an embodiment of the present invention contains 50 mass % or more of an onium salt-type anion-modified microfibrous cellulose having a number average fiber width of 2-1000 nm.
C08B 15/04 - Carboxycellulose, p. ex. préparée par oxydation avec du peroxyde d'azote
D21H 11/18 - Fibres hautement hydratées, gonflées ou aptes à être fibrillées
D21H 15/02 - Pâte ou papier comprenant des fibres ou des matériaux formant des nappes caractérisés autrement que par leur constitution chimique caractérisés par leur configuration
Provided is a converter that is capable of suppressing a spike current generated due to capacitors having a potential difference therebetween being connected to each other, thereby being able to reduce conduction loss of switching elements and noise generation. The converter comprises an inductor L, a plurality of switching elements Q1-Q6, and a plurality of capacitors C1, C2, and Co connected via the switching elements Q1-Q6. A current path of an output current Io passing through the capacitors C1, C2, Co is formed by turn-on of the switching elements Q1-Q6 (complementary turn-on of the switching elements Q1, Q3, Q5 and the switching elements Q2, Q4, Q6). The converter also comprises a sub-inductor Lo inserted into the current path.
H02M 3/155 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 3/07 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des résistances ou des capacités, p. ex. diviseur de tension utilisant des capacités chargées et déchargées alternativement par des dispositifs à semi-conducteurs avec électrode de commande
81.
ACQUISITION METHOD FOR INFORMATION PERTAINING TO SIZE OF NUCLEIC ACID INCLUDED IN VIRUS-DERIVED CAPSID BY USING NANOPORE DEVICE, AND NANOPORE DEVICE AND ACQUISITION DEVICE USED FOR SAID ACQUISITION METHOD
Provided are: an acquisition method for information pertaining to the size of a nucleic acid included in a virus-derived capsid by using a nanopore device; and a nanopore device and an acquisition device used for said acquisition method. The nanopore device includes: a substrate that has a first surface and a second surface; a nanopore that penetrates from the first surface toward the second surface and through which the capsid passes; a first chamber member; and a second chamber member. The first chamber member forms, using the first surface, a first chamber filled with a first electrolytic solution. The second chamber member forms, using the second surface, a second chamber filled with a second electrolytic solution. The acquisition method includes: a capsid passing step for causing the capsid, which is included in the first electrolytic solution or the second electrolytic solution, to pass through the nanopore; and an ion current measurement step for measuring the change in an ion current when the capsid passes through the nanopore.
G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
82.
MATERIAL FOR FORMING X-RAY STRUCTURE ANALYSIS SAMPLE, AND METHOD FOR DETERMINING MOLECULAR STRUCTURE OF ORGANIC COMPOUND USING SAME
Provided is a novel material for forming an X-ray structure analysis sample of an organic compound. A material for forming an X-ray structure analysis sample according to the present disclosure contains the metal complex crystal described below. Metal complex crystal: A metal complex crystal which is composed of a metal ion and a ligand that is coordinated to the metal ion. The metal complex crystal has a three-dimensional network structure that has regularly arranged vacancies, and the ligand includes a carboxylic acid-based ligand (c) and a pyridine-based ligand (p) in a combination of [I] or [II] described below. [I] A compound represented by formula (c1) and a compound represented by formula (p1) [II] A compound represented by formula (c2) and a compound represented by formula (p2)
G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
G01N 23/207 - Diffractométrie, p. ex. en utilisant une sonde en position centrale et un ou plusieurs détecteurs déplaçables en positions circonférentielles
The problem addressed by this invention is to provide a nuclear battery which is lighter in weight and thinner. Said problem is solved by a nuclear battery that includes a thermoelectric conversion element including: a thermoelectric conversion part demonstrating non-reciprocal conduction based on breakage of space inversion symmetry; and a pair of electrodes provided apart from each other in the thermoelectric conversion part and serving to extract a non-reciprocal thermoelectric signal, wherein at least one of the constituents of the nuclear battery includes a radioactive isotope.
G21H 1/10 - Cellules dans lesquelles le rayonnement chauffe une jonction thermo-électrique ou un convertisseur thermo-ionique
H10N 15/20 - Dispositifs thermoélectriques utilisant le changement thermique de la perméabilité magnétique, p. ex. en opérant au-dessus et en-dessous du point de Curie
84.
CATHODE ELECTRODE, COMPOSITE OF CATHODE ELECTRODE AND SUBSTRATE, ELECTROLYTIC REDUCTION APPARATUS HAVING CATHODE ELECTRODE, AND METHOD OF MANUFACTURING COMPOSITE OF CATHODE ELECTRODE AND SUBSTRATE
An example cathode electrode that can stably sustain a catalytic reaction producing an olefinic hydrocarbon such as ethylene and an alcohol such as ethanol by a reduction reaction of carbon dioxide over a long term; and a composite of a cathode electrode and a substrate. An example cathode electrode that electrically reduces carbon dioxide, including: copper; and at least one additive element selected from the group consisting of aluminum, boron, gallium, zinc, titanium, and silicon, wherein the copper contains: zerovalent copper; and monovalent copper and/or divalent copper.
[Problem] To provide a technical improvement for solving or mitigating at least some of the problems of conventional techniques. [Solution] The invention of the present disclosure is based on an unprecedented novel idea of actively changing a charging current, thereby causing the charging current not only to transfer energy, but also to play a role of information transmission. The present disclosure is characterized by comprising an identifying unit that identifies, using second input information or second output information acquired by a second acquisition unit, the identification information of one electric vehicle indicating the second input information having a specific relationship with first output information acquired by a first acquisition unit or the identification information of one charging device indicating the second output information having a specific relationship with first input information. The first output information of a specific charging device or the first input information of a specific electric vehicle varies on the basis of control information for controlling the charging current. The control information causes the charging current to be modulated with a predetermined waveform pattern for a predetermined period.
[Problem] To provide a sheet or the like that has a less pronounced feeling of use when adhered to skin. [Solution] One aspect of the present invention provides a sheet having an adhesion surface that is used facing skin, said sheet including an elastomer and a light scattering material.
The present invention provides a novel metal complex crystal which has regularly arranged vacancies and is capable of forming an X-ray structure analysis sample by fixing an organic compound in the vacancies. A metal complex crystal according to the present disclosure is composed of a metal ion and a ligand, and the ligand includes a carboxylic acid-based ligand (c) and a pyridine-based ligand (p) in a combination selected from among [I]-[IV] described below. [I] compound (c1) and compound (p1) [II] compound (c1) and compound (p2) [III] compound (c2) and compound (p2) [IV] compound (c2) and compound (p3)
B82Y 35/00 - Procédés ou appareils pour la mesure ou l’analyse des nanostructures
C07C 233/81 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle
C07D 213/38 - Radicaux substitués par des atomes d'azote liés par des liaisons simples comportant uniquement de l'hydrogène, ou des radicaux hydrocarbonés, liés à l'atome d'azote substituant
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
G01N 23/20025 - Porte-échantillons ou leurs supports
G01N 23/207 - Diffractométrie, p. ex. en utilisant une sonde en position centrale et un ou plusieurs détecteurs déplaçables en positions circonférentielles
88.
FLAME-RETARDANT COATING AGENT AND FLAME-RETARDANT SHEET
The present invention provides a novel flame-retardant coating agent and flame-retardant sheet including anionically modified fine fibrous cellulose. A flame-retardant coating agent and a flame-retardant sheet according to the embodiments include anionically modified fine fibrous cellulose having a number-average fiber width of 2 to 1,000 nm, wherein counter ions of anionic groups in the anionically modified fine fibrous cellulose include metal ions.
Provided are a fibrous material for thermoforming that contains an anion-modified pulp exhibiting thermoformability, and a composite material for thermoforming. A fibrous material for thermoforming according to an embodiment of the present invention includes an anion-modified pulp in which 45 mol % or more of the anionic group is an onium salt. The composite material for thermoforming according to said embodiment contains an anion-modified pulp in which 45 mol % or more of the anionic group is an onium salt, and a thermoplastic resin.
To provide an antibody that specifically binds to an extracellular domain of human LPA1, wherein the antibody does not specifically bind to an extracellular domain of human LPA2 and does not specifically bind to an extracellular domain of human LPA3. Preferably, the antibody includes an activity of blocking an LPA1-dependent cell function. Also, a nucleic acid encoding the antibody, a cell including the nucleic acid, and a medicament including the antibody as an active ingredient are provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
91.
Classification Model Generation Method, Particle Classification Method, and Recording Medium
A classification model that outputs identification information indicating whether or not a particle has specific morphological characteristics when waveform data is input is generated by training using training data including first waveform data that is obtained by irradiating light to particles contained in a first sample and having specific morphological characteristics and indicates morphological characteristics of the particles, information indicating that the first waveform data has been obtained from particles contained in the first sample, second waveform data indicating morphological characteristics of unspecified particles contained in a second sample, information indicating that the second waveform data has been obtained from particles contained in the second sample, and a positive rate that is the proportion of particles having the specific morphological characteristics.
[Problem]
[Problem]
The present invention provides a dressing material for puncture that allows puncture while observing a blood vessel of a puncture site and a puncture needle with an ultrasound examination device, and allows a puncture device to be directly fixed. Consequently, the present invention provides a dressing material for puncture that avoids entering of air between an adhesive and a skin when the dressing material for puncture is attached and improves not only an ultrasonic transparency but also a moisture permeability.
[Problem]
The present invention provides a dressing material for puncture that allows puncture while observing a blood vessel of a puncture site and a puncture needle with an ultrasound examination device, and allows a puncture device to be directly fixed. Consequently, the present invention provides a dressing material for puncture that avoids entering of air between an adhesive and a skin when the dressing material for puncture is attached and improves not only an ultrasonic transparency but also a moisture permeability.
[Solution]
[Problem]
The present invention provides a dressing material for puncture that allows puncture while observing a blood vessel of a puncture site and a puncture needle with an ultrasound examination device, and allows a puncture device to be directly fixed. Consequently, the present invention provides a dressing material for puncture that avoids entering of air between an adhesive and a skin when the dressing material for puncture is attached and improves not only an ultrasonic transparency but also a moisture permeability.
[Solution]
A dressing material for puncture of the present invention includes a support film, a frame sheet, and a release liner, which are laminated from an upper side in this order. An adhesive is used to bond the support film and the frame sheet, and bond the frame sheet and the release liner. The support film is a base material having a thickness of from 10 μm to 80 μm. The adhesive has a mass per unit area of from 30 g/m2 to 80 g/m2.
A method of treating systemic sclerosis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
94.
INHIBITOR OF INFLAMMATORY CYTOKINE-INDUCED INFLAMMATORY REACTION
The present invention relates to an inflammatory reaction inhibitor that contains sialyllactose or a salt thereof as an active ingredient and suppresses an inflammatory cytokine-induced inflammatory reaction.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
The present invention addresses the problem of providing a relatively low-molecular compound capable of controlling necroptosis. Provided is an agent for treating a disease or condition that is improved by controlling necroptosis, the agent containing a compound represented by formula I or formula II or a pharmacologically acceptable salt thereof. (In formula I and formula II, each of R1, R2, and R31-61-6 alkyl, and X is H or COR4, R 41-622C=CH-.)
This invention provides an antibody that binds specifically to sulfated glycosaminoglycan (sGAG) in a pH-dependent manner. The antibody that binds specifically to sulfated glycosaminoglycan is at least one antibody selected from the group consisting of (1) to (3): (1) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4, CDR2 consisting of the amino acid sequence represented by LGS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6; (2) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10, CDR2 consisting of the amino acid sequence represented by AAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12; and (3) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, CDR2 consisting of the amino acid sequence represented by WAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
This microneedle structure comprises needle-shaped sections to be inserted into an object. The needle-shaped sections have a porous structure. The porous structure includes openings in the side surfaces of the needle-shaped sections, and holes through which a liquid to be injected into the object or a liquid received from the object flows. The side-surface opening count, which is the number of openings per 10,000 μm2 in the side surfaces of the needle-shaped sections, is 30 or greater.
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
B29C 67/20 - Techniques de façonnage non couvertes par les groupes , ou pour la fabrication d'objets poreux ou cellulaires, p. ex. des mousses plastiques, des mousses alvéolaires
C08J 9/26 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase solide d'un objet ou d'une composition macromoléculaire, p. ex. par lessivage
A zinc recovery method includes an alkali fusion step (102) of, at a temperature equal to or higher than a melting point of sodium hydroxide, bringing a material (1) and molten sodium hydroxide being sodium hydroxide (5) or (14) in a molten state into contact with each other to decompose the zinc ferrite contained in the material (1) into zinc oxide components and iron oxide components in the molten sodium hydroxide, a water leaching step (103) of, at a temperature lower than a boiling point of water, bringing water into contact with sodium hydroxide being the molten sodium hydroxide with a decreased temperature, the zinc oxide components, and the iron oxide components and leaching the zinc oxide components in a sodium hydroxide aqueous solution.
C25C 1/16 - Production, récupération ou affinage électrolytique des métaux par électrolyse de solutions du zinc, du cadmium ou du mercure
C22B 3/12 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions inorganiques alcalines
C22B 3/22 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques
C22B 3/44 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés chimiques
The purpose of the present invention is to provide a therapeutic agent and a treatment method that exhibit an excellent therapeutic effect on acute encephalopathy for which no effective treatment method has been found. The present invention is a therapeutic agent for acute encephalopathy that contains umbilical cord-derived mesenchymal cells. Also, the therapeutic agent for acute encephalopathy is preferably for intravenous administration. Furthermore, the umbilical cord-derived mesenchymal cells are preferably cells prepared from umbilical cord tissue including amniotic membrane, blood vessels, perivascular tissues, and Wharton's jelly.
This optical measuring device comprises a light source, an ultrasound wave source, a detector, a control device, and an analysis device. The control device acquires a first speckle image and a second speckle image on the basis of outputs of a detector acquired in a first imaging period and a second imaging period, causes laser light to be emitted in the first imaging period and the second imaging period, and causes oscillation of ultrasound waves from the ultrasound wave source such that the ultrasound waves reach a measuring position. The analysis device calculates a first variation component indicating an amount of variation of speckle in a first region and a second variation component indicating an amount of variation of speckle in a second region between the first speckle image and the second speckle image, and extracts a modulated signal component from the first variation component and the second variation component.
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
G01N 29/06 - Visualisation de l'intérieur, p. ex. microscopie acoustique
